ES2154622T1 - Derivados del taxano hidrofobos. - Google Patents

Derivados del taxano hidrofobos.

Info

Publication number
ES2154622T1
ES2154622T1 ES00121129T ES00121129T ES2154622T1 ES 2154622 T1 ES2154622 T1 ES 2154622T1 ES 00121129 T ES00121129 T ES 00121129T ES 00121129 T ES00121129 T ES 00121129T ES 2154622 T1 ES2154622 T1 ES 2154622T1
Authority
ES
Spain
Prior art keywords
derivative
taxane
carrier
animals
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES00121129T
Other languages
English (en)
Other versions
ES2154622T3 (es
Inventor
Eric Mayhew
J Craig Franklin
Suresh Bhatia
Paul A Harmon
Andrew S Janoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of ES2154622T1 publication Critical patent/ES2154622T1/es
Application granted granted Critical
Publication of ES2154622T3 publication Critical patent/ES2154622T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un derivado del taxano que tiene la fórmula: en la que: - A1 es H o un grupo que tiene la fórmula Q-C(O)NHCH(C6H5)CH(OR)C(O)-; - Q es C6H5-, (CH3)3C-O- o (CH3)CH=C(CH3)-; - A2 es H o CH3C(O)-; - A3 es H o OH; - R y R1 son cada uno independientemente o bien H o restos orgánicos hidrófobos seleccionados de ácidos grasos alifáticos o ramificados saturados o insaturados y en los que al menos uno de R y R1 no es H; en donde cuando R1 es H, A1 es un grupo que tiene la fórmula Q-C(O)NHCH(C6H5)CH(OR)C(O)- y R no es H; y en donde cuando A1 es H o cuando A1 es un grupo que tiene la fórmula Q-C(O)NHCH(C6H5)CH(OR)C(O)- y R es H, R 1 no es H;
ES00121129T 1995-01-09 1996-01-11 Derivados hidrofobos de taxano. Expired - Lifetime ES2154622T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36981795A 1995-01-09 1995-01-09
US08/474,888 US5580899A (en) 1995-01-09 1995-06-07 Hydrophobic taxane derivatives

Publications (2)

Publication Number Publication Date
ES2154622T1 true ES2154622T1 (es) 2001-04-16
ES2154622T3 ES2154622T3 (es) 2003-09-16

Family

ID=27004714

Family Applications (2)

Application Number Title Priority Date Filing Date
ES00121129T Expired - Lifetime ES2154622T3 (es) 1995-01-09 1996-01-11 Derivados hidrofobos de taxano.
ES96903428T Expired - Lifetime ES2163613T3 (es) 1995-01-09 1996-01-11 Derivados hidrofobos de taxano.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96903428T Expired - Lifetime ES2163613T3 (es) 1995-01-09 1996-01-11 Derivados hidrofobos de taxano.

Country Status (13)

Country Link
US (4) US5580899A (es)
EP (2) EP1063234B1 (es)
JP (1) JPH11500712A (es)
KR (1) KR100386002B1 (es)
AT (2) ATE238290T1 (es)
AU (1) AU691401B2 (es)
CA (1) CA2209001C (es)
DE (3) DE69627722T2 (es)
DK (2) DK1063234T3 (es)
ES (2) ES2154622T3 (es)
GR (1) GR20010300005T1 (es)
PT (2) PT802911E (es)
WO (1) WO1996021658A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5580899A (en) 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
EP1229030B1 (en) * 1995-09-12 2005-11-09 Zeneus Pharma Limited Hydrolysis-promoting taxane hydrophobic derivates
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
HU226325B1 (en) * 1995-09-12 2008-08-28 Cephalon Ltd Hydrolysis-promoting hydrophobic taxane derivatives, medicaments comprising them and the use of medicaments
US6667053B1 (en) * 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
JP2000511161A (ja) 1996-05-24 2000-08-29 アンジオテック ファーマシュウティカルズ，インコーポレイテッド 身体通路の疾患を処置または予防するための組成物および方法
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6136988A (en) * 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
NZ513895A (en) * 1999-02-23 2001-09-28 Univ British Columbia Compositions and methods for improving integrity of compromised body passageways and cavities
EP1154782A4 (en) * 1999-02-24 2002-09-25 Uab Research Foundation TAXAN DERIVATIVES FOR TARGETED CANCER THERAPY
WO2000053231A2 (en) * 1999-03-09 2000-09-14 Protarga, Inc. Fatty acid-anticancer conjugates and uses thereof
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
EP1210065B1 (en) * 1999-09-09 2006-05-03 The Regents of the University of California Cationic liposome delivery of taxanes to angiogenic blood vessels
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6362217B2 (en) * 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
US7816398B2 (en) 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
EP1427407A4 (en) 2001-03-23 2005-05-11 Luitpold Pharm Inc CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
WO2002087563A2 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
DE10154464B4 (de) * 2001-11-08 2005-10-20 Max Delbrueck Centrum Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
US20030206893A1 (en) * 2002-05-06 2003-11-06 Sohail Malik Cell proliferating agents
JP4711947B2 (ja) 2003-02-03 2011-06-29 ネオファーム、インコーポレイティッド 安定な濾過滅菌性リポソームに被包化されたタキサン及び他の抗腫瘍剤
CA2598213C (en) * 2005-02-18 2011-04-19 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US8173167B2 (en) * 2005-04-12 2012-05-08 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
EP2222278B1 (en) * 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
WO2009126401A1 (en) * 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
US8236329B2 (en) * 2009-09-25 2012-08-07 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
US9498439B2 (en) * 2010-04-15 2016-11-22 Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
US10842770B2 (en) 2010-05-03 2020-11-24 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
PL226015B1 (pl) 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US20140357706A1 (en) * 2011-10-13 2014-12-04 The Uab Research Foundation Stearate Compounds
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN105853403B (zh) * 2016-05-09 2019-03-29 上海天氏利医药科技有限公司 一种紫杉醇棕榈酸酯脂质体及其制备方法
GEP20217244B (en) * 2016-10-28 2021-04-26 Ag Novartis Liposomal formulation for use in the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
IL95436A (en) * 1989-08-23 1996-07-23 Centre Nat Rech Scient Process for preparing the history of phenylisosarine
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
FR2658510B1 (fr) * 1990-02-21 1992-04-30 Rhone Poulenc Sante Nouveau derive de la beta-phenylisoserine, sa preparation et son emploi.
FR2678930B1 (fr) * 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
FR2680506B1 (fr) * 1991-08-19 1994-09-02 Rhone Poulenc Rorer Sa Procede de preparation de derives de la beta-phenylisoserine et leur utilisation.
WO1993010076A1 (en) * 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
FR2687150B1 (fr) * 1992-02-07 1995-04-28 Rhone Poulenc Rorer Sa Procede de preparation de derives du taxane.
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5200534A (en) * 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives

Also Published As

Publication number Publication date
EP1063234A3 (en) 2001-04-11
EP0802911B1 (en) 2001-11-21
PT1063234E (pt) 2003-09-30
AU4752296A (en) 1996-07-31
CA2209001A1 (en) 1996-07-18
DE69617203T2 (de) 2002-05-08
US5580899A (en) 1996-12-03
DK1063234T3 (da) 2003-06-02
GR20010300005T1 (en) 2001-02-28
WO1996021658A1 (en) 1996-07-18
DK0802911T3 (da) 2002-05-21
ES2163613T3 (es) 2002-02-01
PT802911E (pt) 2002-05-31
US5939567A (en) 1999-08-17
EP1063234A2 (en) 2000-12-27
DE69627722T2 (de) 2003-10-16
JPH11500712A (ja) 1999-01-19
CA2209001C (en) 2007-12-18
KR19980701289A (ko) 1998-05-15
ATE209196T1 (de) 2001-12-15
DE1063234T1 (de) 2001-05-23
ES2154622T3 (es) 2003-09-16
US6118011A (en) 2000-09-12
DE69627722D1 (de) 2003-05-28
US6291690B1 (en) 2001-09-18
DE69617203D1 (de) 2002-01-03
AU691401B2 (en) 1998-05-14
EP1063234B1 (en) 2003-04-23
ATE238290T1 (de) 2003-05-15
KR100386002B1 (ko) 2003-10-10
EP0802911A1 (en) 1997-10-29

Similar Documents

Publication Publication Date Title
ES2154622T1 (es) Derivados del taxano hidrofobos.
DE69310178D1 (de) K-252a DERIVATE
CA2024880A1 (en) 10-(1-hydroxyethyl)-11-oxo-1-azatricyclo(7.2.0.0.3,8)undec-2-ene-2-2-ca rboxylic acid derivatives
LU91854I2 (fr) Eribulin et ses dérivés pharmaceutiquement acceptables (HALAVEN®)
DK0582788T3 (da) 7-(Substituerede)-9-[(substitueret glycyl)-amido]-demethyl-6-deoxytetracycliner
NO921835L (no) Fremgangsmaate for fremstilling av amidinofenylalaninderivat samt anvendelse derav
HUP0003604A2 (hu) Fotoaktív szerekként alkalmazható monohidrobenzoporfirin származékok etilénglikol észterei
AU2328092A (en) Process for the preparation of baccatin iii and 10-deacetyl baccatin iii derivatives
OA08825A (fr) Nouveaux dérivés de l'amino tétrahydro-5,6,7,8 naphto (2,3b) furanne, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
ES2059755T3 (es) Derivados organicos de hidrazina para uso farmaceutico.
FI891581A0 (fi) Peptidderivat.
PT89082A (pt) Processo para a preparacao de novos derivados n-(23-vinblastinoilicos)do acido 1-amino-metilfosfonico
HK1067948A1 (en) Antitumor indolopyprolocarbazole derivative
ZA924888B (en) Process for the synthesis of enantiomers of 3-aminochroman compounds
ATE176242T1 (de) Uck14-verbindungen
NO178302C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte 3-tia- henholdsvis 3-oksa-alkylflavoner, samt mellomprodukter for fremgangsmåten
BG95629A (en) Derivatives of 10, 11, 12, 13 - tetrahytdrodesmicozine, method for preparing them, and their use as pharmaceutical preparations
CA2238710A1 (en) New amino alcohol derivatives, processes for their production and pharmaceutical agents containing these compounds